BMAPN

BMAPN
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act;
Identifiers
	IUPAC name 2-(methylamino)-1-(naphthalene-2-yl) propan-1-one;
CAS Number	109453-73-8;
PubChem CID	112704365;
ChemSpider	65998790;
UNII	DL8RX8N8NK;
CompTox Dashboard (EPA)	DTXSID601337020 ;
Chemical and physical data
Formula	C14H15NO
Molar mass	213.280 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C(=O)C1=CC2=CC=CC=C2C=C1)NC;
	InChI InChI=1S/C14H15NO/c1-10(15-2)14(16)13-8-7-11-5-3-4-6-12(11)9-13/h3-10,15H,1-2H3; Key:QIMNQDXLKHGANJ-UHFFFAOYSA-N;

BMAPN (βk-methamnetamine) is a substituted cathinone derivative with stimulant effects. It inhibits dopamine reuptake and has rewarding and reinforcing properties in animal studies.^[1]^[2] It is banned under drug analogue legislation in a number of jurisdictions. The drug was at one point marketed under the name NRG-3, although only a minority of samples of substances sold under this name have been found to actually contain BMAPN, with most such samples containing mixtures of other cathinone derivatives.^[3]^[4]

References

^ Botanas CJ, Yoon SS, de la Peña JB, Dela Peña IJ, Kim M, Woo T, Seo JW, Jang CG, Park KT, Lee YH, Lee YS, Kim HJ, Cheong JH (January 2017). "A novel synthetic cathinone, 2-(methylamino)-1-(naphthalen-2-yl) propan-1-one (BMAPN), produced rewarding effects and altered striatal dopamine-related gene expression in mice". Behavioural Brain Research. 317: 494–501. doi:10.1016/j.bbr.2016.10.016. PMID 27737791. S2CID 3095092.
^ Simmons SJ, Kim E, Gentile TA, Murad A, Muschamp JW, Rawls SM (2018). "Behavioral Profiles and Underlying Transmitters/Circuits of Cathinone-Derived Psychostimulant Drugs of Abuse.". In Zawilska J (ed.). Synthetic Cathinones. Current Topics in Neurotoxicity. Vol. 12. Cham: Springer. pp. 125–152. doi:10.1007/978-3-319-78707-7_8. ISBN 978-3-319-78706-0.
^ Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J (September 2011). "Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones". Drug Testing and Analysis. 3 (9): 569–75. doi:10.1002/dta.204. PMID 21960541.
^ Eiden C, Mathieu O, Cathala P, Debruyne D, Baccino E, Petit P, Peyriere H (November 2013). "Toxicity and death following recreational use of 2-pyrrolidino valerophenone". Clinical Toxicology. 51 (9). Philadelphia, Pa.: 899–903. doi:10.3109/15563650.2013.847187. PMID 24111554. S2CID 22826544.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[pmid27737791-1] Botanas CJ, Yoon SS, de la Peña JB, Dela Peña IJ, Kim M, Woo T, Seo JW, Jang CG, Park KT, Lee YH, Lee YS, Kim HJ, Cheong JH (January 2017). "A novel synthetic cathinone, 2-(methylamino)-1-(naphthalen-2-yl) propan-1-one (BMAPN), produced rewarding effects and altered striatal dopamine-related gene expression in mice". Behavioural Brain Research. 317: 494–501. doi:10.1016/j.bbr.2016.10.016. PMID 27737791. S2CID 3095092.

[2] Simmons SJ, Kim E, Gentile TA, Murad A, Muschamp JW, Rawls SM (2018). "Behavioral Profiles and Underlying Transmitters/Circuits of Cathinone-Derived Psychostimulant Drugs of Abuse.". In Zawilska J (ed.). Synthetic Cathinones. Current Topics in Neurotoxicity. Vol. 12. Cham: Springer. pp. 125–152. doi:10.1007/978-3-319-78707-7_8. ISBN 978-3-319-78706-0.

[pmid21960541-3] Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J (September 2011). "Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones". Drug Testing and Analysis. 3 (9): 569–75. doi:10.1002/dta.204. PMID 21960541.

[pmid24111554-4] Eiden C, Mathieu O, Cathala P, Debruyne D, Baccino E, Petit P, Peyriere H (November 2013). "Toxicity and death following recreational use of 2-pyrrolidino valerophenone". Clinical Toxicology. 51 (9). Philadelphia, Pa.: 899–903. doi:10.3109/15563650.2013.847187. PMID 24111554. S2CID 22826544.

[1]

[2]

[3]

[4]

BMAPN

See also

References